Oric Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: ORICHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.99-0.04 (-0.33%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Oric Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Oric Pharmaceuticals generated -$31.6 million of operating cash flow and spent $356,000 on capital expenditures. That left free cash flow of -$32.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Oric Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -41.49M | -35.77M | -30.50M | -32.59M | -36.35M | -30.02M | -36.31M | -34.57M | -31.96M | -25.01M | -28.33M | -25.48M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 264.00K | 270.00K | 320.00K | 288.00K | 310.00K | 302.00K | 304.00K | 270.00K | 272.00K | 261.00K | 263.00K | 257.00K |
| Stock-Based Compensation | 7.09M | 6.90M | 6.28M | 5.63M | 6.57M | 6.55M | 5.20M | 5.06M | 5.00M | 4.96M | 3.92M | 3.86M |
| Change in Working Capital | 2.24M | -4.00M | 1.66M | 2.14M | -780.00K | -8.49M | 4.38M | 2.39M | 3.37M | -8.17M | 1.98M | 3.63M |
| Operating Cash Flow | -31.61M | -32.44M | -22.48M | -25.11M | -30.84M | -32.53M | -28.05M | -28.80M | -25.63M | -30.19M | -24.27M | -19.64M |
| Capital Expenditures | -356.00K | -2.00K | -227.00K | -35.00K | -63.00K | -387.00K | -219.00K | -418.00K | -333.00K | -218.00K | -57.00K | -77.00K |
| Investing Cash Flow | 11.86M | -17.98M | 16.98M | -110.53M | -76.93M | 22.45M | 42.66M | 23.07M | 18.28M | -61.87M | 20.96M | -57.83M |
| Financing Cash Flow | 828.00K | 61.14M | 1.50M | 109.45M | 134.30M | 11.00K | 575.00K | 126.00K | 816.00K | 125.03M | 453.00K | 31.00K |
| Net Change in Cash | -18.91M | 10.73M | -4.00M | -26.20M | 26.53M | -10.07M | 15.18M | -5.60M | -6.53M | 32.98M | -2.85M | -77.44M |
| Free Cash Flow | -31.96M | -32.44M | -22.71M | -25.15M | -30.91M | -32.92M | -28.27M | -29.21M | -25.96M | -30.40M | -24.33M | -19.72M |
This table shows 12 quarterly periods of Oric Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ORIC's reporting calendar. What is a cash flow statement?